制酸剤市場：薬剤クラス別、剤形別、適応症別、流通チャネル別-2025-2030年の世界予測

制酸剤市場は、2023年に68億5,000万米ドルと評価され、2024年には72億4,000万米ドルに達すると予測され、CAGR 5.81％で成長し、2030年には101億8,000万米ドルに達すると予測されています。

制酸剤市場には、胃酸を中和し、胃酸逆流、消化不良、胸焼けに伴う症状を緩和することを目的とした市販薬や処方薬が幅広く含まれています。制酸剤の必要性は、不健康な食生活、ストレス、座りがちな生活習慣などのライフスタイル要因によって引き起こされる胃腸疾患が広く蔓延していることに起因しています。制酸剤の用途は、主にヘルスケアや製薬業界であり、消化器系の不快感を即座に緩和する必要のある消費者をターゲットとしています。制酸剤は、高齢者、妊娠中の女性、慢性的な胃腸の問題を抱える人など、多様な層に使用されています。市場の成長を後押ししているのは、胃腸の健康に対する意識の高まり、セルフメディケーションの動向の増加、より幅広い層に訴求するチュアブル錠やフレーバータイプの人気の高まりです。

主な影響要因は、世界の胃腸疾患の増加による消化器系健康市場の急成長です。潜在的な成長機会は、中産階級の人口が増加し、ヘルスケアに対する意識が高まっている新興市場にあります。企業は、砂糖不使用、ビーガン対応、オーガニックなど、健康志向の消費者に応える革新的な製品処方に投資すべきです。しかし、規制上のハードル、長期使用による副作用の可能性、プロトンポンプ阻害薬やH2受容体拮抗薬のような代替治療薬との競合といった課題は、市場の成長を妨げる可能性があります。さらに、誤った情報や適切な使用法に関する認識不足が消費者を迷わせる可能性もあります。

こうした制約を克服するためには、緩和時間の延長、副作用の最小化、患者のコンプライアンス向上を実現する研究開発が必要です。また、即効性のある液体製剤や溶解可能なストリップのような送達メカニズムの強化も、競争力を高める可能性があります。制酸化合物と腸内細菌叢の相互作用に関する先進的な研究は、個別化消化器ケアのための未開発の可能性を提供します。制酸剤市場はダイナミックで消費者主導型であるため、規制や競合がもたらす課題を克服しながら、消費者のニーズや嗜好の変化に対応するための継続的なイノベーションと戦略的マーケティングが必要とされます。

市場力学：急速に進化する制酸剤市場の主要市場インサイトを公開

制酸剤市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 胃食道逆流症を患う人口の増加
  • 世界の国内医薬品製造に対する政府の取り組みと投資
• 市場抑制要因
  • 酸に関連する問題に対する家庭用治療薬やその他の代替品の入手可能性
• 市場機会
  • より即効性があり持続性の高い制酸剤の開発
  • オンライン薬局での制酸剤の容易な入手可能性とOTC医薬品に対する規制の柔軟性
• 市場の課題
  • 制酸剤に関連する医薬品回収と汚染問題

ポーターの5つの力：制酸剤市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：制酸剤市場における外部からの影響の把握

外部マクロ環境要因は、制酸剤市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析制酸剤市場における競合情勢の把握

制酸剤市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス制酸剤市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、制酸剤市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限はベンダーを明確かつ正確に区分し、ユーザーが戦略目標に最適なパートナーやソリューションを特定するのに役立ちます。

本レポートは、主要な注目分野を網羅した包括的な市場分析を提供しています：

1.市場の浸透度：業界主要企業の広範なデータを含む、現在の市場環境の詳細なレビュー。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 胃食道逆流症に苦しむ人口が増加
    • 世界中の国内医薬品製造に対する政府の取り組みと投資
  • 抑制要因
    • 酸性度関連の問題に対する家庭療法やその他の代替療法の利用可能性
  • 機会
    • より即効性があり、持続性のある制酸剤の開発
    • オンライン薬局での制酸剤の容易な入手性とOTC医薬品の規制の柔軟性
  • 課題
    • 制酸剤に関連する医薬品の回収と汚染の問題
• 市場セグメンテーション分析
  • 薬物クラス：治療効果の向上を目的とした酸中和剤の好感度が高まっている
  • 適応症：酸による食道内壁の損傷能力を軽減するための胃食道逆流症の管理に対する制酸剤のニーズの拡大。
  • 処方：すでに溶解した状態で症状の緩和を早めるため、液状制酸剤の好まれている傾向が高まっています。
  • 流通チャネル：処方箋なしで制酸剤を即座に入手できる小売薬局での制酸剤の入手可能性の向上
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 制酸剤市場薬剤クラス別

• 酸中和剤
  • 水酸化アルミニウム
  • 炭酸カルシウム
  • 水酸化マグネシウム
  • 重炭酸ナトリウム
• H2拮抗薬
• プロモーションエージェント
• プロトンポンプ阻害剤

第7章 制酸剤市場処方別

• 液体
• 粉
• 錠剤

第8章 制酸剤市場適応症別

• 胃食道逆流症
• 消化不良/消化不良
• 消化性潰瘍

第9章 制酸剤市場：流通チャネル別

• 病院薬局
• オンライン薬局
• 小売薬局

第10章 南北アメリカの制酸剤市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋地域の制酸剤市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカの制酸剤市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • TUMSはドラフトキングスおよびデサス・ナイスと提携してTUMSプロップバイツを立ち上げ、ビッグゲームファンが初めて食べ物に全力で取り組めるようにしました。
  • デクセルファーマ、消費者向けヘルスケアポートフォリオ強化のためOTCブランド8社を買収
  • キャンバー・ファーマシューティカルズ、ジェネリックのウェルブトリンSRを発売
  • レキットがタミル・ナードゥ州でガビスコン・ダブル・アクションを発売、胃酸過多や胸焼けに悩む人々を助ける
  • ワンダーベリーは、より幅広い顧客層に簡単にアクセスできるよう、ターゲットストア1,800店以上に拡大
  • アップシャー・スミスがファモチジン経口懸濁液を発売
  • ザイダス社、エソメプラゾールマグネシウム製品の米国FDA最終承認を取得
  • ワンダーベリー制酸剤がターゲットに独占フレーバーを提供
  • マークサンズ・ファーマ、ファモチジン錠で米国FDAの承認を取得
  • ENOがジャルジーラとニンブーマサラという2つの新フレーバーでポートフォリオを拡大

企業一覧

• Abbott Laboratories
• Aero Healthcare AU Pty Ltd
• Alcon Industries
• Alkem Laboratories Ltd.
• Allegiant Health
• AstraZeneca plc
• Bayer AG
• Biocon Limited
• Boehringer Ingelheim International GmbH
• Cadila Pharmaceuticals Limited
• Camber Pharmaceuticals, Inc.
• Cipla Limited
• Daiichi Sankyo Company Limited
• Dexcel Ltd.
• Dr. Reddy's Laboratories Ltd.
• GlaxoSmithKline PLC
• Haleon PLC
• Imerys S.A.
• J. B. Chemicals & Pharmaceuticals Limited
• Johnson & Johnson Services, Inc.
• Magmit Pharmaceutical Co., Ltd.
• Mankind Pharma Ltd.
• Marksans Pharma
• Nestle S.A.
• Novartis AG
• Perrigo Company plc
• Pfizer Inc.
• Raritan Pharmaceuticals, Inc.
• Reckitt Benckiser Group PLC
• Sanofi S.A.
• Sun Pharmaceutical Industries Ltd.
• Swiss Chem Healthcare by Swastik Lifesciences
• Takeda Pharmaceutical Company Limited
• Teva Pharmaceutical Industries Ltd.
• The Procter & Gamble Company
• Upsher-Smith Laboratories, LLC by Bora Pharmaceuticals
• Wonderbelly
• Zoic Pharmaceuticals Pvt. Ltd.

LIST OF FIGURES

• FIGURE 1. ANTACIDS MARKET RESEARCH PROCESS
• FIGURE 2. ANTACIDS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL ANTACIDS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL ANTACIDS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL ANTACIDS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL ANTACIDS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL ANTACIDS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL ANTACIDS MARKET SIZE, BY FORMULATION, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL ANTACIDS MARKET SIZE, BY FORMULATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL ANTACIDS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL ANTACIDS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. AMERICAS ANTACIDS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. AMERICAS ANTACIDS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. UNITED STATES ANTACIDS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 17. UNITED STATES ANTACIDS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. ASIA-PACIFIC ANTACIDS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. ASIA-PACIFIC ANTACIDS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ANTACIDS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA ANTACIDS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. ANTACIDS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 23. ANTACIDS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. ANTACIDS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL ANTACIDS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL ANTACIDS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL ANTACIDS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. ANTACIDS MARKET DYNAMICS
• TABLE 7. GLOBAL ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL ANTACIDS MARKET SIZE, BY ALUMINUM HYDROXIDE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL ANTACIDS MARKET SIZE, BY CALCIUM CARBONATE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL ANTACIDS MARKET SIZE, BY MAGNESIUM HYDROXIDE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL ANTACIDS MARKET SIZE, BY SODIUM BICARBONATE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL ANTACIDS MARKET SIZE, BY H2 ANTAGONIST, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL ANTACIDS MARKET SIZE, BY PROMOTILITY AGENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL ANTACIDS MARKET SIZE, BY PROTON PUMP INHIBITOR, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL ANTACIDS MARKET SIZE, BY LIQUID, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL ANTACIDS MARKET SIZE, BY POWDER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL ANTACIDS MARKET SIZE, BY TABLET, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL ANTACIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL ANTACIDS MARKET SIZE, BY GASTROESOPHAGEAL REFLUX DISEASE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL ANTACIDS MARKET SIZE, BY INDIGESTION/DYSPEPSIA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL ANTACIDS MARKET SIZE, BY PEPTIC ULCER DISEASE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL ANTACIDS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL ANTACIDS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL ANTACIDS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. AMERICAS ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 30. AMERICAS ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, 2018-2030 (USD MILLION)
• TABLE 31. AMERICAS ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 32. AMERICAS ANTACIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 33. AMERICAS ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 34. AMERICAS ANTACIDS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 35. ARGENTINA ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 36. ARGENTINA ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, 2018-2030 (USD MILLION)
• TABLE 37. ARGENTINA ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 38. ARGENTINA ANTACIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 39. ARGENTINA ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 40. BRAZIL ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 41. BRAZIL ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, 2018-2030 (USD MILLION)
• TABLE 42. BRAZIL ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 43. BRAZIL ANTACIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 44. BRAZIL ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 45. CANADA ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 46. CANADA ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, 2018-2030 (USD MILLION)
• TABLE 47. CANADA ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 48. CANADA ANTACIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 49. CANADA ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 50. MEXICO ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 51. MEXICO ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, 2018-2030 (USD MILLION)
• TABLE 52. MEXICO ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 53. MEXICO ANTACIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 54. MEXICO ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 55. UNITED STATES ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 56. UNITED STATES ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, 2018-2030 (USD MILLION)
• TABLE 57. UNITED STATES ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 58. UNITED STATES ANTACIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 59. UNITED STATES ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 60. UNITED STATES ANTACIDS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 61. ASIA-PACIFIC ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 62. ASIA-PACIFIC ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, 2018-2030 (USD MILLION)
• TABLE 63. ASIA-PACIFIC ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 64. ASIA-PACIFIC ANTACIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 65. ASIA-PACIFIC ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 66. ASIA-PACIFIC ANTACIDS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 67. AUSTRALIA ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 68. AUSTRALIA ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, 2018-2030 (USD MILLION)
• TABLE 69. AUSTRALIA ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 70. AUSTRALIA ANTACIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 71. AUSTRALIA ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 72. CHINA ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 73. CHINA ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, 2018-2030 (USD MILLION)
• TABLE 74. CHINA ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 75. CHINA ANTACIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 76. CHINA ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 77. INDIA ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 78. INDIA ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, 2018-2030 (USD MILLION)
• TABLE 79. INDIA ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 80. INDIA ANTACIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 81. INDIA ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 82. INDONESIA ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 83. INDONESIA ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, 2018-2030 (USD MILLION)
• TABLE 84. INDONESIA ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 85. INDONESIA ANTACIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 86. INDONESIA ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 87. JAPAN ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 88. JAPAN ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, 2018-2030 (USD MILLION)
• TABLE 89. JAPAN ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 90. JAPAN ANTACIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 91. JAPAN ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 92. MALAYSIA ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 93. MALAYSIA ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, 2018-2030 (USD MILLION)
• TABLE 94. MALAYSIA ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 95. MALAYSIA ANTACIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 96. MALAYSIA ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 97. PHILIPPINES ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 98. PHILIPPINES ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, 2018-2030 (USD MILLION)
• TABLE 99. PHILIPPINES ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 100. PHILIPPINES ANTACIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 101. PHILIPPINES ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 102. SINGAPORE ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 103. SINGAPORE ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, 2018-2030 (USD MILLION)
• TABLE 104. SINGAPORE ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 105. SINGAPORE ANTACIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 106. SINGAPORE ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 107. SOUTH KOREA ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 108. SOUTH KOREA ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, 2018-2030 (USD MILLION)
• TABLE 109. SOUTH KOREA ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 110. SOUTH KOREA ANTACIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 111. SOUTH KOREA ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 112. TAIWAN ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 113. TAIWAN ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, 2018-2030 (USD MILLION)
• TABLE 114. TAIWAN ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 115. TAIWAN ANTACIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 116. TAIWAN ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 117. THAILAND ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 118. THAILAND ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, 2018-2030 (USD MILLION)
• TABLE 119. THAILAND ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 120. THAILAND ANTACIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 121. THAILAND ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 122. VIETNAM ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 123. VIETNAM ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, 2018-2030 (USD MILLION)
• TABLE 124. VIETNAM ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 125. VIETNAM ANTACIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 126. VIETNAM ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 127. EUROPE, MIDDLE EAST & AFRICA ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 128. EUROPE, MIDDLE EAST & AFRICA ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, 2018-2030 (USD MILLION)
• TABLE 129. EUROPE, MIDDLE EAST & AFRICA ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 130. EUROPE, MIDDLE EAST & AFRICA ANTACIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 131. EUROPE, MIDDLE EAST & AFRICA ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 132. EUROPE, MIDDLE EAST & AFRICA ANTACIDS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 133. DENMARK ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 134. DENMARK ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, 2018-2030 (USD MILLION)
• TABLE 135. DENMARK ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 136. DENMARK ANTACIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 137. DENMARK ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 138. EGYPT ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 139. EGYPT ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, 2018-2030 (USD MILLION)
• TABLE 140. EGYPT ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 141. EGYPT ANTACIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 142. EGYPT ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 143. FINLAND ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 144. FINLAND ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, 2018-2030 (USD MILLION)
• TABLE 145. FINLAND ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 146. FINLAND ANTACIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 147. FINLAND ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 148. FRANCE ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 149. FRANCE ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, 2018-2030 (USD MILLION)
• TABLE 150. FRANCE ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 151. FRANCE ANTACIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 152. FRANCE ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 153. GERMANY ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 154. GERMANY ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, 2018-2030 (USD MILLION)
• TABLE 155. GERMANY ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 156. GERMANY ANTACIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 157. GERMANY ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 158. ISRAEL ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 159. ISRAEL ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, 2018-2030 (USD MILLION)
• TABLE 160. ISRAEL ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 161. ISRAEL ANTACIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 162. ISRAEL ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 163. ITALY ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 164. ITALY ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, 2018-2030 (USD MILLION)
• TABLE 165. ITALY ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 166. ITALY ANTACIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 167. ITALY ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 168. NETHERLANDS ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 169. NETHERLANDS ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, 2018-2030 (USD MILLION)
• TABLE 170. NETHERLANDS ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 171. NETHERLANDS ANTACIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 172. NETHERLANDS ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 173. NIGERIA ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 174. NIGERIA ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, 2018-2030 (USD MILLION)
• TABLE 175. NIGERIA ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 176. NIGERIA ANTACIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 177. NIGERIA ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 178. NORWAY ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 179. NORWAY ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, 2018-2030 (USD MILLION)
• TABLE 180. NORWAY ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 181. NORWAY ANTACIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 182. NORWAY ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 183. POLAND ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 184. POLAND ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, 2018-2030 (USD MILLION)
• TABLE 185. POLAND ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 186. POLAND ANTACIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 187. POLAND ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 188. QATAR ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 189. QATAR ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, 2018-2030 (USD MILLION)
• TABLE 190. QATAR ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 191. QATAR ANTACIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 192. QATAR ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 193. RUSSIA ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 194. RUSSIA ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, 2018-2030 (USD MILLION)
• TABLE 195. RUSSIA ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 196. RUSSIA ANTACIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 197. RUSSIA ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 198. SAUDI ARABIA ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 199. SAUDI ARABIA ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, 2018-2030 (USD MILLION)
• TABLE 200. SAUDI ARABIA ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 201. SAUDI ARABIA ANTACIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 202. SAUDI ARABIA ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 203. SOUTH AFRICA ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 204. SOUTH AFRICA ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, 2018-2030 (USD MILLION)
• TABLE 205. SOUTH AFRICA ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 206. SOUTH AFRICA ANTACIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 207. SOUTH AFRICA ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 208. SPAIN ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 209. SPAIN ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, 2018-2030 (USD MILLION)
• TABLE 210. SPAIN ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 211. SPAIN ANTACIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 212. SPAIN ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 213. SWEDEN ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 214. SWEDEN ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, 2018-2030 (USD MILLION)
• TABLE 215. SWEDEN ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 216. SWEDEN ANTACIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 217. SWEDEN ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 218. SWITZERLAND ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 219. SWITZERLAND ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, 2018-2030 (USD MILLION)
• TABLE 220. SWITZERLAND ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 221. SWITZERLAND ANTACIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 222. SWITZERLAND ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 223. TURKEY ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 224. TURKEY ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, 2018-2030 (USD MILLION)
• TABLE 225. TURKEY ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 226. TURKEY ANTACIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 227. TURKEY ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 228. UNITED ARAB EMIRATES ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 229. UNITED ARAB EMIRATES ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, 2018-2030 (USD MILLION)
• TABLE 230. UNITED ARAB EMIRATES ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 231. UNITED ARAB EMIRATES ANTACIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 232. UNITED ARAB EMIRATES ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 233. UNITED KINGDOM ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 234. UNITED KINGDOM ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, 2018-2030 (USD MILLION)
• TABLE 235. UNITED KINGDOM ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 236. UNITED KINGDOM ANTACIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 237. UNITED KINGDOM ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 238. ANTACIDS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 239. ANTACIDS MARKET, FPNV POSITIONING MATRIX, 2023

The Antacids Market was valued at USD 6.85 billion in 2023, expected to reach USD 7.24 billion in 2024, and is projected to grow at a CAGR of 5.81%, to USD 10.18 billion by 2030.

The antacids market encompasses a wide range of over-the-counter and prescription medications intended to neutralize stomach acidity and alleviate symptoms associated with acid reflux, indigestion, and heartburn. The necessity of antacids stems from the widespread prevalence of gastrointestinal diseases caused by lifestyle factors such as unhealthy diets, stress, and sedentary habits. Their application is primarily within the healthcare and pharmaceutical industries, targeting consumers in need of immediate relief from digestive discomfort. Antacids are used by a diverse demographic, including older adults, pregnant women, and individuals with chronic gastrointestinal issues. The market's growth is fueled by rising awareness of gastrointestinal health, increased self-medication trends, and the rising popularity of chewable tablets and flavored versions that appeal to a broader audience.

A key influencing factor is the burgeoning digestive health market, driven by the increase in gastrointestinal diseases globally. Potential growth opportunities reside in emerging markets with a rising middle-class population and increasing healthcare awareness. Companies should invest in innovative product formulations like sugar-free, vegan-friendly, and organic antacids that cater to health-conscious consumers. However, challenges such as regulatory hurdles, the potential side effects of long-term use, and competition from alternative treatments like proton pump inhibitors and H2-receptor antagonists may hinder market growth. Furthermore, misinformation and a lack of awareness regarding appropriate usage can lead consumers astray.

To overcome these limitations, research can be directed towards developing antacids with extended relief duration, minimal side effects, and improved patient compliance. Enhanced delivery mechanisms like fast-acting liquid formulations or dissolvable strips could also provide a competitive edge. Advanced studies on gut microbiota interactions with antacid compounds offer untapped potential for personalized digestive care. The antacids market is dynamic and consumer-driven, requiring continuous innovation and strategic marketing to cater to varying consumer needs and preferences while navigating the challenges posed by regulation and competition.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Antacids Market

The Antacids Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Growing population suffering from gastroesophageal reflux disease
  • Government initiatives and investments for domestic drug manufacturing worldwide
• Market Restraints
  • Availability of home remedies and other alternatives for acidity-related issues
• Market Opportunities
  • Development of more instantly effective and long-lasting antacids
  • Easy availability of antacids in the online pharmacy and regulation flexibility for OTC drugs
• Market Challenges
  • Drug recall and contamination issues associated with the antacids

Porter's Five Forces: A Strategic Tool for Navigating the Antacids Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Antacids Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Antacids Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Antacids Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Antacids Market

A detailed market share analysis in the Antacids Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Antacids Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Antacids Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Antacids Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Aero Healthcare AU Pty Ltd, Alcon Industries, Alkem Laboratories Ltd., Allegiant Health, AstraZeneca plc, Bayer AG, Biocon Limited, Boehringer Ingelheim International GmbH, Cadila Pharmaceuticals Limited, Camber Pharmaceuticals, Inc., Cipla Limited, Daiichi Sankyo Company Limited, Dexcel Ltd., Dr. Reddy's Laboratories Ltd., GlaxoSmithKline PLC, Haleon PLC, Imerys S.A., J. B. Chemicals & Pharmaceuticals Limited, Johnson & Johnson Services, Inc., Magmit Pharmaceutical Co., Ltd., Mankind Pharma Ltd., Marksans Pharma, Nestle S.A., Novartis AG, Perrigo Company plc, Pfizer Inc., Raritan Pharmaceuticals, Inc., Reckitt Benckiser Group PLC, Sanofi S.A., Sun Pharmaceutical Industries Ltd., Swiss Chem Healthcare by Swastik Lifesciences, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., The Procter & Gamble Company, Upsher-Smith Laboratories, LLC by Bora Pharmaceuticals, Wonderbelly, and Zoic Pharmaceuticals Pvt. Ltd..

Market Segmentation & Coverage

This research report categorizes the Antacids Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Drug Class, market is studied across Acid Neutralizers, H2 Antagonist, Promotility Agents, and Proton Pump Inhibitor. The Acid Neutralizers is further studied across Aluminum Hydroxide, Calcium Carbonate, Magnesium Hydroxide, and Sodium Bicarbonate.
• Based on Formulation, market is studied across Liquid, Powder, and Tablet.
• Based on Indication, market is studied across Gastroesophageal Reflux Disease, Indigestion/Dyspepsia, and Peptic Ulcer Disease.
• Based on Distribution Channel, market is studied across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growing population suffering from gastroesophageal reflux disease
    • 5.1.1.2. Government initiatives and investments for domestic drug manufacturing worldwide
  • 5.1.2. Restraints
    • 5.1.2.1. Availability of home remedies and other alternatives for acidity-related issues
  • 5.1.3. Opportunities
    • 5.1.3.1. Development of more instantly effective and long-lasting antacids
    • 5.1.3.2. Easy availability of antacids in the online pharmacy and regulation flexibility for OTC drugs
  • 5.1.4. Challenges
    • 5.1.4.1. Drug recall and contamination issues associated with the antacids
• 5.2. Market Segmentation Analysis
  • 5.2.1. Drug Class: Increasing preference for acid neutralizers for improved therapeutic action
  • 5.2.2. Indication: Expanding need for antacids for the management of gastroesophageal reflux disease for reducing the acid's ability to damage the esophageal lining.
  • 5.2.3. Formulation: Rising preference for liquid antacid due to their already dissolved state, facilitating quicker relief from symptoms
  • 5.2.4. Distribution Channel: Growing availability of antacids across retail pharmacies that provide instant access to antacids without the need for a prescription
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Antacids Market, by Drug Class

• 6.1. Introduction
• 6.2. Acid Neutralizers
  • 6.2.1. Aluminum Hydroxide
  • 6.2.2. Calcium Carbonate
  • 6.2.3. Magnesium Hydroxide
  • 6.2.4. Sodium Bicarbonate
• 6.3. H2 Antagonist
• 6.4. Promotility Agents
• 6.5. Proton Pump Inhibitor

7. Antacids Market, by Formulation

• 7.1. Introduction
• 7.2. Liquid
• 7.3. Powder
• 7.4. Tablet

8. Antacids Market, by Indication

• 8.1. Introduction
• 8.2. Gastroesophageal Reflux Disease
• 8.3. Indigestion/Dyspepsia
• 8.4. Peptic Ulcer Disease

9. Antacids Market, by Distribution Channel

• 9.1. Introduction
• 9.2. Hospital Pharmacy
• 9.3. Online Pharmacy
• 9.4. Retail Pharmacy

10. Americas Antacids Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Antacids Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Antacids Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
  • 13.3.1. TUMS Teams Up with DraftKings and Desus Nice to Launch TUMS Prop Bites, Allowing Big Game Fans to Go All In on Food for the First Time
  • 13.3.2. Dexcel Pharma Acquires 8 OTC Brands to Strengthen its Consumer Healthcare Portfolio
  • 13.3.3. Camber Pharmaceuticals Launches Generic Wellbutrin SR
  • 13.3.4. Reckitt Launches Gaviscon Double Action in Tamil Nadu, Helping People with Acidity and Heartburn
  • 13.3.5. Wonderbelly Expands To Over 1,800 Target Stores to be Easily Accessible to a Broader Audience
  • 13.3.6. Upsher-Smith Launches Famotidine For Oral Suspension
  • 13.3.7. Zydus Secures Final Approval from the USFDA for its Esomeprazole Magnesium Product
  • 13.3.8. Wonderbelly Antacid Brings Exclusive Flavor to Target With Launch
  • 13.3.9. Marksans Pharma Gets USFDA Nod for Famotidine Tablets
  • 13.3.10. ENO Expands its Portfolio with Two New Flavors, Jaljeera and Nimbu Masala

Companies Mentioned

• 1. Abbott Laboratories
• 2. Aero Healthcare AU Pty Ltd
• 3. Alcon Industries
• 4. Alkem Laboratories Ltd.
• 5. Allegiant Health
• 6. AstraZeneca plc
• 7. Bayer AG
• 8. Biocon Limited
• 9. Boehringer Ingelheim International GmbH
• 10. Cadila Pharmaceuticals Limited
• 11. Camber Pharmaceuticals, Inc.
• 12. Cipla Limited
• 13. Daiichi Sankyo Company Limited
• 14. Dexcel Ltd.
• 15. Dr. Reddy's Laboratories Ltd.
• 16. GlaxoSmithKline PLC
• 17. Haleon PLC
• 18. Imerys S.A.
• 19. J. B. Chemicals & Pharmaceuticals Limited
• 20. Johnson & Johnson Services, Inc.
• 21. Magmit Pharmaceutical Co., Ltd.
• 22. Mankind Pharma Ltd.
• 23. Marksans Pharma
• 24. Nestle S.A.
• 25. Novartis AG
• 26. Perrigo Company plc
• 27. Pfizer Inc.
• 28. Raritan Pharmaceuticals, Inc.
• 29. Reckitt Benckiser Group PLC
• 30. Sanofi S.A.
• 31. Sun Pharmaceutical Industries Ltd.
• 32. Swiss Chem Healthcare by Swastik Lifesciences
• 33. Takeda Pharmaceutical Company Limited
• 34. Teva Pharmaceutical Industries Ltd.
• 35. The Procter & Gamble Company
• 36. Upsher-Smith Laboratories, LLC by Bora Pharmaceuticals
• 37. Wonderbelly
• 38. Zoic Pharmaceuticals Pvt. Ltd.